vs
Side-by-side financial comparison of FVCBankcorp, Inc. (FVCB) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $16.9M, roughly 1.1× FVCBankcorp, Inc.). On growth, FVCBankcorp, Inc. posted the faster year-over-year revenue change (4377.5% vs 1808.5%). Over the past eight quarters, FVCBankcorp, Inc.'s revenue compounded faster (586.6% CAGR vs 268.5%).
FVCBankcorp, Inc. is a Virginia-based U.S. bank holding company operating FVCbank, a community-focused financial institution. It provides a full range of personal and commercial banking products including deposit accounts, business and personal loans, mortgage services, and wealth management solutions, serving SMEs, professionals and individual consumers across the Mid-Atlantic region.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
FVCB vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.9M | $18.6M |
| Net Profit | — | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 43.7% | 56.3% |
| Net Margin | — | 65.7% |
| Revenue YoY | 4377.5% | 1808.5% |
| Net Profit YoY | — | 376.5% |
| EPS (diluted) | $0.31 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.9M | $18.6M | ||
| Q3 25 | $416.0K | $334.0K | ||
| Q2 25 | $15.8M | $1.4M | ||
| Q1 25 | $382.0K | $257.0K | ||
| Q4 24 | $378.0K | $977.0K | ||
| Q3 24 | $412.0K | $660.0K | ||
| Q2 24 | $415.0K | $736.0K | ||
| Q1 24 | $359.0K | $1.4M |
| Q4 25 | — | $12.3M | ||
| Q3 25 | $5.6M | $-8.6M | ||
| Q2 25 | $5.7M | $-6.9M | ||
| Q1 25 | $5.2M | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $4.7M | $-2.8M | ||
| Q2 24 | $4.2M | $-14.5M | ||
| Q1 24 | $1.3M | $411.0K |
| Q4 25 | 43.7% | 56.3% | ||
| Q3 25 | — | -2516.5% | ||
| Q2 25 | 45.9% | -701.0% | ||
| Q1 25 | — | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1563.6% | ||
| Q2 24 | — | -1255.0% | ||
| Q1 24 | — | -692.5% |
| Q4 25 | — | 65.7% | ||
| Q3 25 | 1341.1% | -2572.2% | ||
| Q2 25 | 36.0% | -504.8% | ||
| Q1 25 | 1352.1% | -2097.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | 1133.3% | -425.5% | ||
| Q2 24 | 1001.2% | -1964.4% | ||
| Q1 24 | 373.3% | 29.9% |
| Q4 25 | $0.31 | $0.25 | ||
| Q3 25 | $0.31 | $-0.17 | ||
| Q2 25 | $0.31 | $-0.14 | ||
| Q1 25 | $0.28 | $-0.11 | ||
| Q4 24 | $0.27 | — | ||
| Q3 24 | $0.25 | $-0.06 | ||
| Q2 24 | $0.23 | $-0.30 | ||
| Q1 24 | $0.07 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $253.6M | $49.4M |
| Total Assets | $2.3B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $253.6M | $49.4M | ||
| Q3 25 | $249.8M | $36.4M | ||
| Q2 25 | $243.2M | $44.5M | ||
| Q1 25 | $242.3M | $50.5M | ||
| Q4 24 | $235.4M | $55.1M | ||
| Q3 24 | $230.8M | $58.5M | ||
| Q2 24 | $226.5M | $60.4M | ||
| Q1 24 | $220.7M | $74.1M |
| Q4 25 | $2.3B | $59.0M | ||
| Q3 25 | $2.3B | $51.1M | ||
| Q2 25 | $2.2B | $60.7M | ||
| Q1 25 | $2.2B | $67.9M | ||
| Q4 24 | $2.2B | $90.6M | ||
| Q3 24 | $2.3B | $99.0M | ||
| Q2 24 | $2.3B | $107.8M | ||
| Q1 24 | $2.2B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $23.9M | $18.4M |
| Free Cash FlowOCF − Capex | $23.8M | — |
| FCF MarginFCF / Revenue | 140.7% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $40.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.9M | $18.4M | ||
| Q3 25 | $7.6M | $-8.7M | ||
| Q2 25 | $3.3M | $-7.5M | ||
| Q1 25 | $5.4M | $-7.5M | ||
| Q4 24 | $18.2M | $-24.0M | ||
| Q3 24 | $4.7M | $765.0K | ||
| Q2 24 | $1.6M | $-10.9M | ||
| Q1 24 | $7.2M | $-4.0M |
| Q4 25 | $23.8M | — | ||
| Q3 25 | $7.6M | — | ||
| Q2 25 | $3.3M | — | ||
| Q1 25 | $5.4M | — | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $4.6M | — | ||
| Q2 24 | $1.5M | — | ||
| Q1 24 | $7.1M | — |
| Q4 25 | 140.7% | — | ||
| Q3 25 | 1818.0% | — | ||
| Q2 25 | 20.8% | — | ||
| Q1 25 | 1413.6% | — | ||
| Q4 24 | 4786.0% | — | ||
| Q3 24 | 1121.8% | — | ||
| Q2 24 | 361.2% | — | ||
| Q1 24 | 1988.3% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 37.3% | — | ||
| Q3 24 | 14.1% | — | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | 3.9% | — |
| Q4 25 | — | 1.50× | ||
| Q3 25 | 1.36× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.00× | — | ||
| Q2 24 | 0.37× | — | ||
| Q1 24 | 5.34× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVCB
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
